Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Purpose To test the efficacy of 4 weeks of intravenous (IV) induction with high-dose interferon (IFN) as part of the Eastern Cooperative Oncology Group regimen compared with observation (OBS) in patients with surgically resected intermediate-risk melanoma. Patients and Methods In this intergroup international trial, eligible patients had surgically resected cutaneous melanoma in the following categories: (1) T2bN0, (2) T3a-bN0, (3) T4a-bN0, and (4) T1-4N1a-2a (microscopic). Patients were randomly assigned to receive IFN α-2b at 20 MU/m2/d IV for 5 days (Monday to Friday) every week for 4 weeks (IFN) or OBS. Stratification factors were pathologic lymph node status, lymph node staging procedure, Breslow depth, ulceration of the primary lesion, and disease stage. The primary end point was relapse-free survival. Secondary end points included overall survival, toxicity, and quality of life. Results A total of 1,150 patients were randomly assigned. At a median follow-up of 7 years, the 5-year relapse-free survival rate was 0.70 (95% CI, 0.66 to 0.74) for OBS and 0.70, (95% CI, 0.66 to 0.74) for IFN ( P = .964). The 5-year overall survival rate was 0.83 (95% CI, 0.79 to 0.86) for OBS and 0.83 (95% CI, 0.80 to 0.86) for IFN ( P = .558). Treatment-related grade 3 and higher toxicity was 4.6% versus 57.9% for OBS and IFN, respectively ( P < .001). Quality of life was worse for the treated group. Conclusion Four weeks of IV induction as part of the Eastern Cooperative Oncology Group high-dose IFN regimen is not better than OBS alone for patients with intermediate-risk melanoma as defined in this trial.

[1]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Hauschild,et al.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.

[3]  H. Gogas,et al.  Intravenous high‐dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta‐analysis of three trials , 2015, Cancer medicine.

[4]  A. Enk,et al.  Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Ascierto,et al.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[6]  P. Lorigan,et al.  Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Cui,et al.  A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients. , 2011, European journal of cancer.

[8]  M. Mandalà,et al.  Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Gray,et al.  Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  U. Dafni,et al.  Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Alan Agresti,et al.  Unconditional small-sample confidence intervals for the odds ratio. , 2002, Biostatistics.

[13]  N. Cascinelli,et al.  Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial , 2001, The Lancet.

[14]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Chastang,et al.  Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases , 1998, The Lancet.

[17]  M. Binder,et al.  Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Dodge,et al.  The annual risk of melanoma progression. Implications for the concept of cure , 1992, Cancer.

[19]  Charles M. Balch,et al.  Predicting survival and recurrence in localized melanoma: A multivariate approach , 1992, World Journal of Surgery.

[20]  A I Goldman,et al.  Survivorship analysis when cure is a possibility: a Monte Carlo study. , 1984, Statistics in medicine.

[21]  B. Turnbull,et al.  Repeated confidence intervals for group sequential clinical trials. , 1984, Controlled clinical trials.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  J BERKSON,et al.  Calculation of survival rates for cancer. , 1950, Proceedings of the staff meetings. Mayo Clinic.

[24]  M Greenwood,et al.  Experimental Epidemiology: Some General Considerations , 1926, Proceedings of the Royal Society of Medicine.

[25]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[26]  M. Gordon Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2009 .

[27]  J. Kirkwood,et al.  Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. , 2000, Cytokines, cellular & molecular therapy.

[28]  C. Chastang,et al.  Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. , 1998, Lancet.

[29]  J C Briggs,et al.  Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.

[30]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[31]  D.,et al.  Regression Models and Life-Tables , 2022 .